Definium Therapeutics is developing DT120, a 100 µg oral LSD therapy for GAD and MDD, with modelled annual pricing of $28,000 to $70,000 and an eight-hour monitoring requirement.

Formerly MindMed, Definium is preparing DT120 for potential commercialisation after positive Phase 3 results in generalized anxiety disorder and major depressive disorder. The company has not set a final price and is assessing whether a flexible discharge window can improve cost-effectiveness, as patients may need up to eight hours of supervised observation.